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Heart failure is one of the most prevalent causes of death in the 
world. There are many different diseases affecting the heart. For 
many of them, the only answer is a heart transplant. Although this 
has saved countless lives, transplants remain an imperfect solution. 
Firstly, the list of people requiring new hearts is a long one, but the 
amount of donor hearts available is few. Once a patient is approved 
for a heart transplant, s/he is added to a waiting list, which is part 
of a national allocation system run by the Organ Procurement 
and Transplantation Network (OPTN). There are approximately 
3,500 people on the list, and waiting times can range from about 
six months to more than a year. 
Even once a heart is found for the patient, and the transplant is 
successful, the patient is still not out of danger. Although the heart 
itself is healthy, it may not function properly in the recipient, caus-
ing a number of complications. One such concern is Primary Graft 
Dysfunction, which is the most frequent cause of death in the first 
30 days after a transplant (National Institutes of Health, 2012). 
According to the OPTN, the one year survival rate for patients 
in the U.S. aged 18-34 is almost 85%, with 75% 3 year survival 
rate, and 66% five year. The 1, 3 and 5 year survival rate for recipi-
ents age 35-50 is slightly higher, at 88%, 81% and 74% respectively 
(OPTN). Although these numbers are relatively high, one of the 
main causes for heart transplant failure in the first year after the 
transplant is due to the patient’s immune system rejecting the 
foreign organ. To prevent this, immunosuppressant drugs are ad-
ministered; however, this can cause damage to other organs such 
as the kidneys and liver. High cholesterol, diabetes and cancer are 
also some risks of the anti-rejection drugs (Bhimji, 2011). The gap 
between the supply and demand for donor organs, as well as the 
lifelong consequences for the patient, make the creation and im-
plantation of a bioartificial heart a desirable alternative. While the 
construction of a functional whole organ has not yet been accom-
plished, tissue engineering and regenerative medicine research 
have obtained promising results for heart regeneration.
Bioengineers have been working on creating fully functioning or-
gans that would eliminate the need for donors. This would solve 
the issue of patients not receiving a heart in time, in addition to 
getting rid of any concerns of rejection. There have been many 
studies done all in the hope of answering the question, is growing 
a new heart for a patient a foreseeable goal of the near future?
When trying to solve such a complicated issue there are numer-
ous factors that must be taken into account, and many different 
angles that the problem can be studied through. With the case 
of the engineered heart, some of those factors include finding a 
suitable base, or scaffold for the organ, deciding what kind of cells 
would be appropriate for actually building the organ, and matur-
ing the construct to develop some form of contractile and pump 
function. 
Methods
The information in this paper was obtained by analysis of scien-
tific articles and research papers. Various online databases and 
medical journals were used, accessed mostly via PubMed or the 
Touro College database. Most of the information is based on ex-
periments done using rat cells since this is the most practical way 
of obtaining the large quantity of cells needed. Although the data 
is not completely applicable to human cardiac cells, researchers 
hope that these studies will provide insight into bioengineering of 
human hearts. 
Discussion 
The first major issue in organ engineering is creating a scaffold 
with enough elasticity, porosity, and strength to enable the cells 
to grow correctly, thus resulting in a functioning organ or tissue. 
The makeup of the scaffold is vital to the process because native 
tissues contain different cell types, with each cell type having its 
own unique three-dimensional (3-D) extracellular matrix environ-
ment, and mechanical properties. In addition, there are many other 
structures that must be taken into account, such as blood vessels. 
An ideal construct should display the functional and structural 
properties of natural heart muscle, and therefore should be con-
tractile, vascularized, and electrophysiologically stable. To recreate 
such complexity in engineered tissues various approaches have 
been used. 
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Much of the research on cardiac tissue engineering that has been 
done was focused more on small sections of tissue than on the 
whole heart. However, this can be an important start to full organ 
engineering, as the results of such studies can be incorporated 
into studies dedicated to heart engineering. 
Scientists have approached the issue of scaffolds from many differ-
ent angles. In one such approach, cells are seeded on a degradable 
scaffold on which they reorganize into engineered tissues. 
A group of bioengineers set out to research different designs for 
scaffolds to determine which would be most conducive to cardiac 
tissue growth. They were able to create two layer scaffolds, with 
fully interconnected pore networks, which aided in guiding the 
pattern of cell growth. The material used was a synthetic elas-
tomer poly(glycerol sebacate), known as PGS. This polymer was 
chosen because of its ability to reproduce the mechanical stiff-
ness and elasticity of the extracellular matrix. Additionally, PGS is 
supportive of blood vessel formation, and cardiogenesis. Different 
scaffolds were created with different properties, such as pore size, 
and thickness. Two layer scaffolds 200μm in total thickness, with 
interconnected pores were found to be the most effective for al-
lowing heart cells to survive and form functional connections. PGS 
scaffolds provided a platform for patterned cell distribution while 
maintaining the geometric and mechanical properties of normal 
heart muscle (Neal, et al., 2013). A similar study done at Duke 
University used the flexible material PDMS (polyDimethylsilox-
ane) to create molds with elliptical pores. Such pores enabled the 
enhanced diffusion of oxygen and nutrients to the cells (Liau, et 
al., 2011).
In addition to the design for the scaffold, researchers must deter-
mine what kind of material should be used. One material, called 
Poly(N-isopropylacrylamide) or PNIPAAm, is a polymer recently 
emerging as a possibility due to its favorable properties. PNIPAAm 
has controllable features and switchable surface properties, making 
it an ideal option for scaffold formation. For example, PNIPAAm 
has a lower critical solution temperature (LCST) of 32oC. This is 
important because it will shrink and become hydrophobic at tem-
peratures above the LCST, and hydrophilic at temperatures below. 
Whereas hydrophobic surfaces are attractive for cell attachment, 
detachment of cells and tissues from these templates requires 
either an enzymatic reaction or physical scraping, both of which 
can damage the cells. The use of PNIPAAm enabled controlled cell 
detachment by adjusting the temperature (Tekin, et al., 2011).
Another advantage to using PNIPAAm is its dynamic properties. 
Previously, micromolds were used to create microgels. However, 
these scaffolds had static structures, meaning the surface proper-
ties and patterns could not be changed after fabrication. PNIPAAm 
gel molds were able to be engineered to control 3-D organization 
of the cells by mimicking the complex native tissue architecture. 
Additionally, the polymer is a hydrogel, which would enable blood 
vessels to form in the organ. Coating surfaces in PNIPAAm served 
to induce capillary network formation. This is especially important 
for tissues to function properly (Tekin, et al., 2011).
Recently, a group of scientists experimented with adding sin-
gle-wall carbon nanotubes (SWCNTs) to PNIPAAm to improve 
the function of the base gel for use in myocardial repair. SWCNTs 
are sheets of graphene rolled into a seamless cylinder. They have 
remarkable electrical properties, which may even exceed the best 
metals or semiconductors known, as experiments have shown 
(McEuen, et al., 2002). They theorized that the SWCNTs would 
improve the bioactivites and adhesion of the hydrogel to the cells. 
After the cells were applied to the gel, it was observed that as 
expected, cell adhesion and proliferation was about 1.71 times 
greater in the PNIPAAm/SWCNT hydrogel than in the PNIPAAm. 
The results indicated that the incorporation of SWCNTs greatly 
enhanced the bioactivity of the PNIPAAm and aided in its func-
tioning as a scaffold (Li, et al., 2014). Finding a suitable material for 
the scaffold is one main step in the process of tissue engineering. 
Another option recently being explored for use as scaffolds, are 
decellularized organs. As mentioned previously, even if donor or-
gans were not in short supply, the transplant recipient would still 
be at risk of immune rejections and lifelong immunosuppression 
treatment. To date, although numerous modern technologies have 
been employed to fabricate new tissues, the creation of a func-
tioning whole organ is still in progress. The use of decellularized 
matrices would be a step in the right direction, as it would over-
come the need for the bioengineer to artificially recreate the con-
ditions for cell deposition. It would offer a microenvironment with 
preserved natural geometry and vascular networks, which would 
enable cells to grow in the correct patterns (Moroni , Mirabella, 
2014). 
In one such study, hearts were decellularized with detergents, 
which preserved the underlying ECM, providing acellular, per-
fusable vascular architecture, and intact chamber geometry. All 
cellular material which would induce an immune response, such 
as cardiac and smooth muscle cells, DNA, RNA and soluble pro-
teins, were removed. This left behind only the collagen, laminins 
and other structural proteins as a scaffold. Fiber orientation and 
composition remained intact, as did the arterial and venous base-
ment membranes. As shown in figure 1, the detergent SDS was 
successful in removing all cells, while the Triton detergent left cells 
behind (Ott, et al., 2008).
The scaffold or decellularized organ now must be seeded with 
cells. This leads to the next issue regarding tissue engineering: what 
kind of cells should be used. Many researchers in the field use a 
mixture of two or more cell types, such as endothelial precur-
sor cells to line blood vessels, and muscle progenitors, which are 
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similar to stem cells, to seed the walls of the chambers. These can 
be derived from induced pluripotent stem (iPS) cells- adult cells 
genetically reprogrammed to an embryonic stem cell-like state, 
which can be coaxed by scientists to become any kind of cell. This 
is useful because these can be taken from the patient, and used 
to make immunologically matched tissues (Maher, 2013). A team 
from the University of Pittsburgh recently used iPS cells generated 
from human skin cells to create precursor heart cells called MCPs. 
The cells were placed on a decellularized scaffold, and grew and 
developed into heart muscle. After 20 days, the tissue began show-
ing cardiac muscle function (Discovery News, 2013). 
 Alternatively, as in a different study, heart cells were isolated from 
neonatal rats and digested in a trypsin solution until dissociated 
into a single cell suspension. Other steps were done to isolate the 
cells, and at the end of this method 63% cardiomyocytes, 33% car-
diac fibroblasts, 3-4% smooth muscle cells and 2-3% endothelial 
cells were collected to be used to seed the scaffold (Neal, et at., 
2013). Tissues constructed from these heart cell mixtures showed 
advanced structure, determining that creation of optimal cardiac 
tissue constructs depends on a mix of non-monocytes and cardiac 
monocytes (Zimmermann, et al., 2004).
A group of scientists using similar neonatal cells performed ex-
periments to determine the effect of different factors on the 
growth of the cells in cultures and on the scaffold. For example, 
by analyzing the gas and CO2 levels in different vessels, they were 
able to determine what environment would be best for the cell 
growth. Additionally, by analyzing the density of the seeded cells, 
they determined that the minimal cell seeding density necessary 
to maintain construct structural integrity was achieved by using 
1.4x106 cells per scaffold. For interconnected tissue structure, 
8x106 cells per scaffold were required. From all the collected data, 
the researchers concluded that structural and functional proper-
ties of constructs were improved by seeding polymer scaffolds 
at high densities using rotating vessels. This study demonstrated 
that dissociated cells cultured on 3D scaffolds under favorable 
conditions were capable of forming engineered constructs with 
features resembling those of native tissues (Carrier, et al., 1998). 
Other favorable properties for cell growth were determined in 
another study. Various factors were tested for their role in engi-
neered heart tissue. High collagen content in the mixture yielded 
tissue with higher stiffness, but less contractile force development. 
Decreasing the collagen content yielded tissue with soft matrix 
structure, but improved contractile properties. Additionally, the in-
clusion of horse serum was found to be beneficial for engineered 
heart tissue development (Zimmermann, et al., 2004). 
Once the scaffold is prepared and the cells cultured and seeded, 
the next step is to observe and determine whether the cells will 
behave as cardiac muscle cells. This includes being able to contract, 
and electrically conduct signals. While full engineered heart trans-
plants have not been perfected, scientists have been successful on 
smaller scales. Biomedical engineers at Duke University were able 
to grow a three dimensional human heart muscle that acted like 
Figure 1: 
Hearts decellularized using different detergents. Asterisks indicate intact vascular network. 
Source: Ott HC, et al. 2008
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natural tissue, in that it conducted electricity at about the same 
speed as natural heart cells, and contracted appropriately (Duke 
University, 2013). Using pluripotent embryonic stem cells perme-
ated with fibroblasts, cardiac tissue was created with the capabil-
ities of generating fast, uniform action potential propagation with 
velocities ranging from 17.8cm/s to 24.1 cm/s, and contractile 
force of 2mN (Liau, et al., 2011).
With the decellularization method, the recellularized hearts were 
placed in bioreactors that mimicked the sensation of beating. A 
combination of electrical signals was used to help synchronize the 
cardiocytes seeded on the scaffold, along with physical beating 
motions induced by a pump. After eight to ten days in the biore-
actor the hearts were able to beat by themselves. However, when 
the team implanted the engineered hearts into rats, none of the 
hearts were able to perform the blood-pumping function at the 
degree that is required of the heart (Maher, 2013).
In a study done in Tokyo, layered cell sheets coated with PNIPAAm 
were created and implanted into the hearts of rats. At first the 
beating of engineered tissue, at 96bpm, was relatively slow in com-
parison to host hearts, 332bpm; after four weeks it had gotten 
stronger, though not as fast as the host tissue. A positive factor 
was that neovascularization occurred in the tissue, which aided it 
in functioning properly (Shimizu, et al., 2002).
In a different experiment, engineered heart tissue was created and 
implanted onto an infarcted area in rat hearts. When evaluated 
later, the engineered tissue showed electrical impulses in synch 
with the native tissue. It was also evident that the implanted tis-
sue had prevented further dilation and induced wall thickening of 
infarcted myocardial segments. The epicardial activation of hearts 
with the tissue graft was normal, indicating undelayed coupling of 
the grafted tissue to the host tissue. The tissue was also able to 
propagate electrical potentials (Zimmermann, et al., 2006). This 
shows that tissue created in vitro can possibly function as natural 
cardiac tissue in vivo.
Conclusion
Although a completely functioning heart has not yet been engi-
neered, scientists are headed in the right direction. Using scaffolds 
made of different materials and with different designs, they have 
been able to stimulate cell growth in the right patterns for tissue 
construction. Under the right conditions, the constructs behaved 
in a manner similar to native cardiac tissue. Such engineered tis-
sues have even been shown to function almost as well as natural 
tissue in vivo. With the integration of these different aspects, and 
advances in bioengineering, scientists are getting closer to the goal 
of creating a fully functioning artificial heart. 
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